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ORIGINAL INVESTIGATION
TNF-α induces vascular insulin resistance 
via positive modulation of PTEN and decreased 
Akt/eNOS/NO signaling in high fat diet-fed mice
Rafael Menezes da Costa1*, Karla Bianca Neves1, Fabíola Leslie Mestriner1, Paulo Louzada‑Junior2, 
Thiago Bruder‑Nascimento1 and Rita C. Tostes1
Abstract 
Background: High fat diet (HFD) induces insulin resistance in various tissues, including the vasculature. HFD also 
increases plasma levels of TNF‑α, a cytokine that contributes to insulin resistance and vascular dysfunction. Consider‑
ing that the enzyme phosphatase and tension homologue (PTEN), whose expression is increased by TNF‑α, reduces 
Akt signaling and, consequently, nitric oxide (NO) production, we hypothesized that PTEN contributes to TNF‑α‑
mediated vascular resistance to insulin induced by HFD. Mechanisms underlying PTEN effects were determined.
Methods: Mesenteric vascular beds were isolated from C57Bl/6J and TNF‑α KO mice submitted to control or HFD 
diet for 18 weeks to assess molecular mechanisms by which TNF‑α and PTEN contribute to vascular dysfunction.
Results: Vasodilation in response to insulin was decreased in HFD‑fed mice and in ex vivo control arteries incubated 
with TNF‑α. TNF‑α receptors deficiency and TNF‑α blockade with infliximab abolished the effects of HFD and TNF‑α on 
insulin‑induced vasodilation. PTEN vascular expression (total and phosphorylated isoforms) was increased in HFD‑fed 
mice. Treatment with a PTEN inhibitor improved insulin‑induced vasodilation in HFD‑fed mice. TNF‑α receptor dele‑
tion restored PTEN expression/activity and Akt/eNOS/NO signaling in HFD‑fed mice.
Conclusion: TNF‑α induces vascular insulin resistance by mechanisms that involve positive modulation of PTEN and 
inhibition of Akt/eNOS/NO signaling. Our findings highlight TNF‑α and PTEN as potential targets to limit insulin resist‑
ance and vascular complications associated with obesity‑related conditions.
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Background
Obesity is an important cause of morbidity and mor-
tality worldwide [1, 2]. Overweight and obesity trigger 
metabolic abnormalities such as dyslipidemia, insulin 
resistance and vascular dysfunction, which contribute to 
the development of type 2 diabetes and cardiovascular 
diseases [3].
Insulin plays an important role on vascular tone con-
trol [4–6]. Insulin binding to the insulin receptor (IR) 
activates the phosphatidylinositol 3-kinase (PI3K)/Akt 
signaling pathway, resulting in endothelial nitric oxide 
synthase (eNOS) activation, nitric oxide (NO) release and 
vasodilation [7, 8]. Vascular insulin resistance is consid-
ered a primary defect in vascular dysfunction [9], and 
inflammatory mediators are potential contributors to 
insulin resistance [10].
Obesity is often associated with resistance to vascu-
lar actions of insulin [11]. Obesity is also tightly related 
to high levels of inflammatory mediators, including the 
cytokine tumor necrosis factor-alpha (TNF-α) [12]. 
TNF-α content is increased in murine adipose tissue, and 
increased circulating TNF-α levels are reported in obese 
humans and experimental animal models of obesity [13].
It is well established that TNF-α induces insulin resist-
ance [14, 15]. In the vasculature TNF-α reduces IRS-1 
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phosphorylation and decreases NO release by the PI3K/
Akt/eNOS pathway [16]. Moreover, blockade of TNF-α 
in obese rats increases vascular sensitivity to insulin and 
mice lacking TNF-α receptors remain insulin sensitive 
when submitted to high-fat diet (HFD) [17].
Although various studies demonstrated a crosstalk 
between TNF-α and insulin resistance, the mechanisms 
involved remain to be elucidated. Preliminary evidence 
indicates that increased levels of the enzyme phos-
phatase and tensin homologue (PTEN), widely impli-
cated as a negative regulator of insulin/Akt signaling 
[18], negatively affect insulin sensitivity [19]. A recent 
study showed that PTEN haploinsufficiency is a mono-
genic cause of profound constitutive insulin sensitization. 
Moreover, PTEN mutations increase risks of obesity and 
cancer but decreases risk of type 2 diabetes [20], show-
ing that in fact proteins related to metabolism and cell 
growth are closely associated with the development of 
metabolic diseases.
TNF-α is closely linked to PTEN regulation [21]. In 
human leukemic cells TNF-α increases PTEN protein 
expression via various nuclear transcription factors [22]. 
In addition, TNF-α increases PTEN phosphorylation 
in C2C12 cells, a mouse myoblast cell line, leading to 
insulin resistance [23]. Selective PTEN deletion in skel-
etal muscle protects against the development of fat- and 
age-dependent insulin resistance [24]. However, it is not 
known whether a similar mechanism takes place in the 
vasculature or whether such mechanism contributes to 
insulin resistance associated with HFD/obesity.
Therefore, the present study tested the hypothesis that 
HFD induces vascular insulin resistance via increased 
PTEN activity and impaired Akt/eNOS signaling. In 
addition, we investigated whether TNF-α triggers PTEN-
mediated vascular insulin resistance in HFD-fed animals.
Methods
Animals and diets
All experimental protocols were performed in accord-
ance with the Ethical Principles in Animal Experimen-
tation approved by the Brazilian College of Animal 
Experimentation (COBEA) and were approved by the 
Ethics Committee on Animal Use (CEUA) of the Univer-
sity of Sao Paulo, Ribeirao Preto Campus, Brazil (Proto-
col no 149/2014).
Five week-old male C57Bl/6J and TNF-α receptor-
deficient mice (TNF-α KO) were obtained from the 
Laboratory of Molecular Immunology and Embryology, 
Transgenose Institute, Centre National de la Recherche 
Scientifique (CNRS), Orléans, France and maintained 
in the Animal Facility of the University of Sao Paulo, 
Ribeirao Preto, Brazil on 12-h light/dark cycles under 
controlled temperature (22 ± 1 °C) with ad libitum access 
to food and water. After a one-week acclimatization 
period, mice were divided into 2 groups: (1) mice main-
tained in control diet (protein 22  %, carbohydrate 70  % 
and fat 8  % of energy, PragSolucoes); (2) mice receiv-
ing HFD (protein 10 %, carbohydrate 25 % and fat 65 % 
of energy, PragSolucoes) for 18  weeks. After the treat-
ment period, mice were killed by carbon dioxide (CO2) 
inhalation.
Nutritional and metabolic profile of high fat diet‑induced 
obese mice
Nutritional profile was weekly determined by analyzing 
the caloric intake, feed efficiency, body weight and body 
fat. Caloric intake (per mouse) was calculated by the 
weekly food intake multiplied by the dietary energetic 
value. Feeding efficiency, defined by the ability to trans-
form consumed calories into body weight, was deter-
mined with the formula: mean body weight gain (g)/total 
calorie intake. Animal body weight was measured weekly 
and obesity was defined using the adiposity index ([body 
fat (g)/final body weight (g)] × 100). Body fat was calcu-
lated by summing the epididymal, retroperitoneal and 
visceral fat [25]. After 18 weeks of HFD, glucose concen-
trations were determined in serum samples from mice 
fasted for 12 h, using an enzymatic colorimetric glucose 
oxidase method (Doles®). Plasma insulin concentration 
(ng/mL) was determined by radioimmunoassay (Insu-
lin Kit®). Insulin sensitivity was calculated using the 
HOMA-IR index (Homeostasis Model Assessment) [26], 
which takes into account insulin and fasting blood glu-
cose levels, using the following mathematical formula: 
HOMA-IR = fasting insulin × fasting glucose/22.5.
Oral glucose tolerance test
The oral glucose tolerance test (OGTT) was performed 
to evaluate glucose tolerance. Mice were deprived of 
food for 6  h. Blood was sampled from the caudal vein 
immediately before (baseline, t0) and after (t15, t30, t60, t90, 
t120 min) administration of 2 g of glucose/kg by oral gav-
age. Glucose levels were determined using a glucose ana-
lyzer (Accu-Check, Roche Diagnostics).
Assessment of vascular function
Mesenteric vascular beds were isolated from C57Bl/6J 
and TNF-α KO mice fed with control diet or HFD. Sec-
ond-order branches of the superior mesenteric artery 
were dissected and mounted on a wire myograph (DMT, 
Danish Myo Technology, Aarhus, Denmark). Vessel seg-
ments (2  mm in length) were mounted on 25  µm wires 
in a vessel bath chamber for isometric tension recording 
and equilibrated for 30  min in Krebs-Henseleit-modi-
fied physiological salt solution (120  mM NaCl, 25  mM 
NaHCO3, 4.7  mM KCl, 1.18  mM KH2PO4, 1.18  mM 
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MgSO4, 2.5  mM CaCl2, 0.026  mM EDTA, and 5.5  mM 
glucose), at 37  °C, continuously bubbled with 95  % O2 
and 5  % CO2, pH 7.4. At the beginning of each experi-
ment, arteries were contracted with KCl 120  mM to 
test for functional integrity. Endothelial function was 
assessed by testing the relaxant effect of acetylcholine 
(ACh, 2  µM) on vessels contracted with phenylephrine 
(PE, 2  µM). Rings exhibiting a vasodilator response to 
ACh greater than 80  % were considered endothelium-
intact vessels. Concentration–response curves to Insulin 
(10−10–10−5  M) were performed in endothelium-intact 
arteries to assess insulin-dependent relaxation. In some 
protocols, arteries were pre-incubated with a vanadium 
complex that acts as a highly potent and specific phos-
phorylation inhibitor of PTEN [27] (VO-OHpic, 10−4 
M), TNF-α (5 ng/mL), TNF-α inhibitor (Infliximab, 10−6 
M), Akt activator (YS-49, 10−6 M) or eNOS inhibitor 
(L-NAME, 10−5 M), 60 min prior to the concentration–
response curves.
Nitric oxide metabolites levels
The mesenteric bed, free from adipose tissue, was imme-
diately frozen in liquid nitrogen, pulverized and homog-
enized in 20  mM Tris–HCl (pH 7.4). The samples were 
centrifuged (5000×g, 10  min, 4  °C) and the total pro-
tein content was quantified using the Bradford method 
(Bio-Rad) [28]. The samples were analyzed in duplicate 
for nitrite and nitrate (NOx) using chemiluminescence-
based assay ozone. Briefly, mesenteric bed samples were 
treated with cold ethanol (1:2 mesenteric bed to ethanol, 
for 30 min at −20 °C) and centrifuged (4000×g, 10 min). 
NOx levels were measured by injecting 25 μL of superna-
tant in a container vent glass containing 0.8 % of Vana-
dium (III) in HCl (1  N) at 90  °C, which reduces NOx 
into NO gas. A stream of nitrogen was bubbled through 
the purge vessel containing vanadium (III) with sodium 
hydroxide [NaOH (1 N)], and then through an analyzer 
(Sievers Nitric Oxide Analyzer® 280, GE Analytical 
Instruments, Boulder, CO, USA).
Fluorescence detection of nitric oxide production
NO production was determined by the fluorescent NO 
indicator, 5,6 Diaminofluorescein diacetate (DAF-2 
DA). Mesenteric arteries were embedded in Tissue Tek® 
O.C.T. Compound (Sakura Finetek, Torrance, CA, USA). 
Unfixed frozen cross Sects.  (5 μm) were incubated with 
DAF-2 DA (12.5 μM; Sigma) diluted in phosphate buffer 
with CaCl2 (0.4 mM) and insulin (2 µM); in a light pro-
tected and humidified chamber at 37 °C for 1 h. Fluores-
cence was detected with a 490–515  nm long-pass filter, 
under a microscope (Olympus, BX50) with a 100× objec-
tive lens coupled to a digital camera. Fluorescent images 
were analyzed by measuring the mean optical density of 
the fluorescence in a computer system (Image J software) 
and normalized by the area.
Western Blot analysis
Mesenteric vascular beds were frozen in liquid nitro-
gen and homogenized in a buffer (50  mM Tris/HCl, 
150 mM NaCl, 1 % Nonidet P40, 1 mM EDTA, 1 μg/ml 
leupeptin, 1 μg/ml pepstatin, 1 μg/ml aprotinin, 1 mM 
sodium orthovanadate, 1 mM PMSF and 1 mM sodium 
fluoride). Proteins were extracted (60  μg) and sepa-
rated by electrophoresis on 10  % polyacrylamide gel, 
and transferred on to nitrocellulose membranes. Non-
specific binding sites were blocked with 5  % BSA in 
TBS containing 0.1 % Tween 20 (for 1 h at 24 °C). Mem-
branes were incubated with antibodies (at the indicated 
dilutions) overnight at 4  °C. Antibodies were used as 
follows: Phospho-Akt(Ser473) (1:1000 dilution; Cell Sign-
aling Technology), Phospho-eNOS(Ser1177) (1:500 dilu-
tion; Cell Signaling Technology), Phospho-eNOS(Thr495) 
(1:500 dilution; Cell Signaling Technology), PTEN 
(1:500 dilution; Cell Signaling Technology), Phospho-
PTEN (1:500 dilution; Cell Signaling Technology) and 
anti-β-actin (1:3000 dilution; Abcam). After incubation 
with secondary antibodies, signals were obtained by 
chemiluminescence, visualized by autoradiography and 
quantified densitometrically.
Plasma TNF‑α level
Plasma TNF-α concentration was measured with mTNF-
alpha DuoSet ELISA assay kit (DY410-R&D Systems, 
USA).
Compounds
Phenylephrine, acetylcholine, L-NAME, VO-OHpic and 
YS-49 were purchased from Sigma Chemical Co (St. 
Louis, MO, USA). Insulin (Insunorm®) was purchased 
from Aspen Pharma. Infliximab (Remicade®) was pur-
chased from Janssen Biologics.
Data and statistical analyses
Relaxation responses to Insulin are expressed as a per-
centage of contraction in response to PE. The indi-
vidual concentration–response curves were fitted into 
a curve by non-linear regression analysis. pD2 (defined 
as the negative logarithm of the EC50 values) and maxi-
mal response (Emax) values were compared by Two-way 
analysis of variance (ANOVA) followed by the Bonferroni 
post hoc test. The Prism software, version 5.0 (GraphPad 
Software Inc., San. Diego, CA, USA) was used to analyze 
these parameters as well as to fit the sigmoidal curves. 
Data are presented as mean  ±  SEM. N represents the 
number of animals used p values less than 0.05 were con-
sidered significant.
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Results
Metabolic parameters in C57Bl/6J and TNF‑α KO mice fed 
with control and high‑fat diets
After 18 weeks on the HFD there was a marked increase 
in all nutritional and anthropometric parameters both 
in C57Bl/6J mice and in TNF-α KO mice (Table 1) com-
pared with animals on the control diet. No difference 
in glucose tolerance, determined by the OGTT, was 
observed between C57Bl/6J mice and TNF-α KO mice 
fed with control diet. HFD decreased glucose tolerance 
in C57Bl/6J, whereas TNF-α deletion partially protected 
from HFD-induced glucose intolerance (Fig.  1a, b). In 
addition, insulin plasma levels and HOMA-IR index were 
increased in HFD-fed C57Bl/6J mice compared with their 
control mice. TNF-α deficiency partially prevented the 
increase in insulin plasma levels and HOMA-IR index 
(Fig. 1c, d).
TNF‑α reduces vascular relaxation
As shown in Fig.  2a HFD-fed C57Bl/6J mice exhibited 
a 6.5-fold increase in plasma TNF-α levels compared 
with control mice. Figure  2b–d and Table  2 show that 
TNF-α contributes to reduced acetylcholine and insulin-
induced vasodilation in HFD-fed mice. No difference was 
observed in vasodilation between C57Bl/6J and TNF-α 
KO mice fed with control diet. HFD reduced acetylcho-
line and insulin-induced vascular relaxation in C57Bl/6J 
mice. However, TNF-α deletion prevented HFD-induced 
vascular dysfunction (Fig.  2b, c). Endothelium removal 
abolished insulin-induced vasodilation in all groups. 
In addition, no significant differences were observed in 
relaxation mediated by sodium nitroprusside between 
wild-type and TNF-α KO mice or between control and 
HFD mice (not shown).
To assess direct effects of TNF-α in the vasculature, 
vessels were incubated with infliximab, a chimeric mono-
clonal antibody against TNF-α. Infliximab did not affect 
insulin-induced vascular relaxation in C57Bl/6J mice fed 
with the control diet. However, infliximab augmented 
insulin vasodilation in HFD-fed C57Bl/6J mice (Fig. 2d).
TNF‑α and PTEN‑dependent mechanisms contribute 
to vascular insulin resistance in HFD‑fed mice
Figure 3a, b illustrates total and phosphorylated levels of 
PTEN in the mesenteric bed of the experimental groups. 
HFD treatment increased vascular PTEN protein expres-
sion, as well as PTEN phosphorylation levels in C57Bl/6J 
mice, effects not seen in vessels from TNF-α KO mice. To 
assess whether PTEN is involved in HFD-induced vascu-
lar insulin resistance, mesenteric vessels from C57Bl/6J 
mice, fed with control or HFD, were incubated with a 
PTEN inhibitor (VO-OHpic) (Fig. 3c; Table 3). The PTEN 
inhibitor did not affect relaxation in arteries from control 
mice. However, VO-OHpic completely prevented vascu-
lar insulin resistance in vessels from HFD-fed C57Bl/6J 
mice. In addition, control vessels incubated with recom-
binant TNF-α exhibited decreased insulin-induced relax-
ation. Concomitant incubation of vessels with TNF-α 
and the PTEN inhibitor prevented the effects of TNF-α 
on insulin vasodilation (Fig. 3d; Table 4). In this context, 
TNF-α increased PTEN phosphorylation, which was 
reversed in the presence of PTEN inhibitor (Fig. 3e).
HFD‑induced obesity impairs Akt/NO signaling pathway 
by TNF‑α‑dependent mechanisms
In order to elucidate the mechanisms involved on the 
crosstalk between TNF-α and PTEN, which affects the 
sensitivity of mesenteric arteries to insulin, the role of 
Table 1 Characteristics of C57Bl/6J and TNF-α receptors deficient mice fed with control and high fat diets
Results are expressed as mean ± SEM. * p < 0.05 vs. respective control. n = 8–10 in each experimental group
Control diet Control diet High fat diet High fat diet
C57Bl/6J TNF‑α KO C57Bl/6J TNF‑α KO
Initial body mass (g) 20.9 ± 0.5 20.6 ± 0.3 21.7 ± 0.4 21.2 ± 0.4
Final body mass (g) 28.8 ± 0.6 26.6 ± 0.6 42.5 ± 0.8* 40.9 ± 0.9*
Caloric intake (kcal/week) 74.8 ± 0.5 74.2 ± 0.5 91.4 ± 1.0* 94.8 ± 0.8*
Weight gain (g) 7.9 ± 0.4 5.9 ± 0.3 20.8 ± 0.9* 18.8 ± 1.1*
Feed efficiency (g/kcal) ×100 0.3 ± 0.04 0.2 ± 0.04 0.8 ± 0.08* 0.8 ± 0.03*
Epididymal fat (g) 0.50 ± 0.02 0.47 ± 0.03 4.41 ± 0.07* 4.13 ± 0.07*
Visceral fat (g) 0.15 ± 0.02 0.12 ± 0.02 2.85 ± 0.03* 2.77 ± 0.04*
Retroperitoneal fat (g) 0.14 ± 0.07 0.15 ± 0.03 2.99 ± 0.03* 1.78 ± 0.04*
Total fat (g) 0.79 ± 0.05 0.77 ± 0.09 10.25 ± 0.11* 8.72 ± 0.21*
Adiposity index (%) 2.24 ± 0.1 1.77 ± 0.2 13.27 ± 0.6* 12.25 ± 0.7*
Glycemia (mg/dL) 100.1 ± 2.4 96.8 ± 3.1 192.9 ± 3.7* 188.7 ± 1.3*
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PTEN on the modulatory effects of TNF-α in vascular 
NO bioavailability was evaluated. The nitric oxide syn-
thase inhibitor L-NAME significantly reduced insulin 
vasodilation in C57Bl/6J mice on control diet. L-NAME 
also effectively reduced insulin-induced relaxation in ves-
sels incubated with TNF-α and PTEN inhibitor (Fig. 4a; 
Table  4), indicating that PTEN activity is involved on 
TNF-α-induced decreased NO bioavailability in mesen-
teric arteries.
As TNF-α increases PTEN activity, reducing Akt activ-
ity [21] and NO release, we investigated whether TNF-α 
decreases insulin-induced vascular relaxation by interfer-
ing with Akt/NO signaling in HFD-fed mice.
The vasculature of HFD-fed C57Bl/6J mice exhibited 
reduced phosphorylation levels of Akt (Ser473), which 
was not observed in vessels from HFD-fed TNF-α KO 
mice (Fig. 4b). To determine whether Akt signaling path-
way is involved on insulin vascular resistance in HFD-fed 
mice, vessels were pre-incubated with an Akt activator, 
YS-49, prior to the concentration-effect curves to insu-
lin (Fig.  4c; Table  4). The Akt activator restored insulin 
relaxation in mesenteric arteries from HFD-fed C57Bl/6J 
mice. YS-49 did not change insulin-induced vascular 
relaxation in mice fed with the control diet.
Signaling downstream to Akt, i.e. phosphorylation 
levels of eNOS (at Ser1177 and Thr495, stimulatory and 
inhibitory sites, respectively), was also analyzed (Fig. 4d). 
Vessels from HFD-fed C57Bl/6J mice presented reduced 
levels of phosphorylated eNOS at Ser1177 residue and 
increased levels of phosphorylated eNOS at Thr495 resi-
due. Vessels from HFD-fed TNF-α receptor deficient 
mice exhibited increased Ser1177 phosphorylation levels 
and decreased Thr495 phosphorylation.
To confirm that reduced vascular eNOS (Ser1177) 
phosphorylation levels in HFD-fed C57Bl/6J mice are 
associated with reduced NO release, NO levels were 
determined by using two techniques: the fluorescent NO 
indicator (DAF-2 DA) (Fig. 4e) and measurement of NO 
metabolites levels (Fig.  4f ). The vasculature of HFD-fed 
C57Bl/6J mice exhibited decreased NO formation, which 
was not observed in vessels from HFD-fed TNF-α KO 
mice.
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Fig. 1 TNF‑α contributes to glucose intolerance and increased insulin levels in HFD‑fed mice. OGTT was performed in C57Bl/6J and TNF‑α KO mice 
fed with control or HFD diets (for 18 weeks). After a 6 h‑fasting period, baseline blood glucose was measured. Mice received 2 mg/kg glucose by 
gavage and blood samples were collected at 30, 60, 90 and 120 min after the challenge (a). Area under the curve (AUC) in the plot of blood glucose 
concentration against time (b). Insulin plasma levels (c). HOMA‑IR index (d). Results represent the mean ± S.E.M. n = 7–8 in each experimental 
group. *p < 0.05 vs. C57Bl/6J Control, #p < 0.05 vs. C57Bl/6J HFD
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Discussion
Obesity induces various structural and functional 
changes in the vasculature, compromising the integ-
rity and function of the cardiovascular system. The pre-
sent study investigated mechanisms by which TNF-α 
decreases vascular insulin sensitivity consequent to a 
HFD. The key finding of our study is that HFD increases 
TNF-α circulating levels, which increases PTEN phos-
phatase activity, impairing Akt/eNOS/NO signaling 
pathway and compromising vascular relaxation.
High fat diet and TNF‑α
Obesity development is usually associated with con-
sumption of diets rich in fat and carbohydrates [29]. 
Increased body mass associated with fat accumulation is 
an important criterion for obesity characterization [30]. 
In the present study HFD significantly increased adi-
posity index and triggered the accumulation of adipose 
tissue in C57Bl/6J mice. These conditions facilitate devel-
opment of co-morbidities that result in increased glucose 
levels and body mass. Of importance, TNF-α KO mice 
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Fig. 2 TNF‑α decreases vascular relaxation in HFD‑fed mice. Plasma TNF‑α levels (a). Concentration‑effect curves to acetylcholine and insulin 
were performed in endothelium‑intact mesenteric resistance arteries of C57Bl/6J and TNF‑α KO mice fed with control or HFD diets (b, c). The 
role of TNF‑α on the vasculature was investigated using infliximab in vessels of C57Bl/6J fed with control or HFD diet (d). Results represent the 
mean ± S.E.M. n = 5–6 in each experimental group. *p < 0.05 vs. C57Bl/6J Control; #p < 0.05 vs. C57Bl/6J HFD
Table 2 pD2 and  Emax (%) values of  acetylcholine and  insulin-induced relaxation in  mesenteric arteries of  control or 
HFD-fed mice incubated with vehicle or infliximab
Data represent the mean ± SEM of n experiments. Two-way ANOVA with Bonferroni post-test. * p < 0.05 vs. C57Bl/6J Control; # p < 0.05 vs. C57Bl/6J HFD
Groups pD2 Emax
Control HFD Control HFD
C57Bl/6J (acetylcholine) 7.29 ± 0.06 (n = 6) 6.80 ± 0.04 (n = 6)* 92.8 ± 1.9 (n = 6) 59.9 ± 1.8 (n = 6)*
TNF‑α−/− (acetylcholine) 7.16 ± 0.02 (n = 6) 6.94 ± 0.04 (n = 6)# 94.4 ± 2.1 (n = 6) 87.8 ± 1.3 (n = 6)#
C57Bl/6J (insulin) 7.01 ± 0.15 (n = 5) 6.02 ± 0.18 (n = 6)* 80.8 ± 2.7 (n = 5) 52.8 ± 6.8 (n = 5)*
TNF‑α−/− (insulin) 6.84 ± 0.51 (n = 5) 6.91 ± 0.20 (n = 6)# 84.4 ± 2.1 (n = 5) 86.7 ± 2.9 (n = 5)#
C57Bl/6J_Infliximab 7.03 ± 0.14 (n = 5) 6.69 ± 0.21 (n = 6)# 85.0 ± 1.8 (n = 5) 63.7 ± 2.2 (n = 5)*
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Fig. 3 Vascular PTEN protein phosphorylation modulates insulin‑induced relaxation in HFD‑fed mice. Western blot quantification of total (a) and 
phosphorylated (b) PTEN expression levels in mesenteric arteries. Concentration‑effect curves to insulin were performed in endothelium‑intact 
resistance mesenteric arteries. The role of PTEN in the vasculature was investigated using VO‑OHpic in vessels of C57Bl/6J mice fed with control and 
HFD diets (c) and vessels of C57Bl/6J incubated with TNF‑α (d). Western blot quantification of phosphorylated PTEN expression levels in mesenteric 
arteries (e). Results represent the mean ± S.E.M. n = 5–6 in each experimental group. *p < 0.05 vs. C57Bl/6J Control; #p < 0.05 vs. C57Bl/6J HFD; 
&p < 0.05 vs. C57Bl/6J Control_TNF‑α
Table 3 pD2 and  Emax (%) values of  insulin-induced relaxation in  mesenteric arteries of  control or HFD-fed mice incu-
bated with vehicle, VO-OHpic or TNF-α
Data represent the mean ± SEM of n experiments. Two-way ANOVA with Bonferroni post-test. * p < 0.05 vs. C57Bl/6J Control; # p < 0.05 vs. C57Bl/6J HFD; & p < 0.05 vs. 
C57Bl/6J_TNFα
Groups pD2 Emax
Control HFD Control HFD
C57Bl/6J 7.01 ± 0.15 (n = 5) 6.02 ± 0.18 (n = 6)* 80.8 ± 2.7 (n = 5) 52.8 ± 6.8 (n = 5)*
C57Bl/6J_VO‑OHpic 6.93 ± 0.22 (n = 5) 6.87 ± 0.11 (n = 7)# 86.9 ± 1.9 (n = 5) 78.0 ± 4.1 (n = 5)#
C57Bl/6J_TNF‑α 6.30 ± 0.14 (n = 6)* – 49.4 ± 2.7 (n = 6) –
C57Bl/6J_TNF‑α + VO‑OHpic 7.29 ± 0.13 (n = 6)& – 63.5 ± 1.6 (n = 6)*& –
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fed with HFD for 18 weeks also showed increased body 
weight, increased adiposity index and serum glucose 
levels, indicating that the differences found in vascular 
function between C57Bl/6J and TNF-α KO mice do not 
depend on the improvement of body mass profile or body 
composition phenotype.
Obesity is also characterized by the development 
of a chronic low-grade inflammation. The concept of 
metabolic inflammation came from the identification 
of high levels of circulating TNF-α, an inflammatory 
cytokine associated with lipid [31] and carbohydrates 
[32] metabolism. Accordingly, HFD-fed C57Bl/6J mice 
exhibited increased TNF-α plasma levels. TNF-α and 
other cytokines have been described as biomarkers of 
cardiovascular risk in metabolic diseases. For instance, 
patients with type 2 diabetes mellitus and hypertension 
show severe increase of serum TNF-α [33], which is sig-
nificantly attenuated by acetylsalicylic acid [34]. In this 
context, TNF-α blockade has antiatherosclerotic effects 
in hyperlipidemic mice lacking apoE [35].
High fat intake is associated with major risk factors for 
development of type 2 diabetes mellitus and cardiovascu-
lar disorders [36]. Mice fed with HFD exhibited glucose 
tolerance and increased plasma levels of insulin. The 
lack of TNF-α receptors partially protected against these 
metabolic abnormalities, in line with previous reports. 
Uysal (1997) demonstrated that TNF-α deficient mice are 
protected against HFD-induced increased glucose and 
insulin levels, but not body weight gain [37]. In addition, 
TNF-α or TNF-α receptors deficient mice are protected 
against obesity-induced insulin resistance and hyper-
glycemia [38, 39]. Furthermore, TNF-α blocks glucose 
uptake by inhibiting insulin-stimulated tyrosine kinase 
activity of the insulin receptor in various cell types, 
including adipocytes, hepatocytes and muscle cells [40].
TNF‑α and vascular insulin resistance
Insulin directly contributes to vascular tone control [41–
43]. Insulin stimulates NO production by mechanisms 
involving activation of PI3K/Akt/eNOS signaling in the 
endothelial layer. Insulin-induced vasodilation increases 
blood flow and stimulates glucose uptake by the skel-
etal muscle, thereby linking metabolic and hemodynamic 
homeostasis [44].
Vascular insulin resistance is characterized by the ina-
bility of a tissue to respond to insulin [45] and vascular 
insulin resistance is associated with decreased NO pro-
duction. In this study HFD promoted insulin resistance 
in the vasculature and deletion of TNF-α receptors pre-
vented this effect. TNF-α is involved in endothelial dys-
function and reduced NO release in obese individuals 
[46, 47]. TNF-α also favors release of contractile media-
tors [48], such as COX-2-derived products and reactive 
oxygen species (ROS) [49]. Of importance, endothelial 
dysfunction evoked by TNF-α is reduced in fit and well-
controlled type 1 diabetes mellitus patients [50]. In addi-
tion, TNF-α plays an important role in the changes of 
macrovascular and microvascular circulation. Oleate, the 
main lipid component of virgin olive oil, protects against 
cardiovascular insulin resistance and improves endothe-
lial dysfunction in response to TNF-α [51].
An important finding of this study is that infliximab 
increased insulin sensitivity of mesenteric arteries from 
HFD-fed C57Bl/6J mice, indicating a synergic effect between 
Table 4 pD2 and  Emax (%) values of  insulin-induced relaxation in  mesenteric arteries of  control or HFD-fed mice incu-
bated with vehicle, VO-OHpic, TNF-α or L-NAME
Date represent the mean ± SEM of n experiments. Two-way ANOVA with Bonferroni post-test. * p < 0.05 vs. C57Bl/6J Control; # p < 0.05 vs. C57Bl/6J HFD; & p < 0.05 vs. 
C57Bl/6J_TNFα + VO-OHpic
Groups pD2 Emax
Control HFD Control HFD
C57Bl/6J 7.01 ± 0.15 (n = 5) 6.02 ± 0.18 (n = 6)* 80.8 ± 2.7 (n = 5) 52.8 ± 6.8 (n = 5)*
C57Bl/6J_YS‑49 6.99 ± 0.19 (n = 5) 7.12 ± 0.10 (n = 6)# 91.8 ± 1.3 (n = 5)* 83.7 ± 2.0 (n = 5)#
C57Bl/6J_L‑NAME 6.30 ± 0.14 (n = 6)* – 47.4 ± 4.7 (n = 6)* –
C57Bl/6J_TNF‑α + VO‑OHpic 7.29 ± 0.13 (n = 6) – 63.5 ± 1.6 (n = 6) –
C57Bl/6J_TNF‑α + VO‑OHpic + L‑NAME 6.49 ± 0.23 (n = 6)& – 33.5 ± 5.6 (n = 6)& –
(See figure on next page.) 
Fig. 4 TNF‑α contributes to decreased Akt/NO signaling in HFD‑fed mice. Concentration‑effect curves to insulin were performed in endothelium‑
intact mesenteric arteries. The role of the PTEN on TNF‑α‑modulate NO in vessels was investigated using L‑NAME (a). Western blot quantification of 
Akt(Ser473) phosphorylation levels in mesenteric arteries (b). The role of Akt on the relaxation was investigated using YS‑49 in vessels of C57Bl/6J mice 
fed with control or HFD diet (c). Western blot quantification of mesenteric arteries eNOS(Ser1177/Thr495) phosphorylation levels in mesenteric arteries 
(d). DAF‑2 DA‑derived fluorescence (e). NO metabolites levels (f). Results represent the mean ± S.E.M. n = 5–6 in each experimental group. Scale bar: 
100 µm. *p < 0.05 vs. C57Bl/6J Control; #p < 0.05 vs. C57Bl/6J HFD; &p < 0.05 vs. C57Bl/6J_TNFα + VO‑OHpic
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TNF-α produced by the vasculature and circulating TNF-α. 
Infliximab treatment has anti-inflammatory effects in the 
vasculature and improves endothelium-dependent vasomo-
tor responses in patients with systemic vasculitis [52].
Crosstalk between TNF‑α, PTEN and vascular dysfunction
It is well known that TNF-α interferes with vascular ben-
eficial effects of insulin, possibly at the level of IRS [53]. 
Our results show the involvement of PTEN on TNF-α-
induced reduced vascular insulin responses. There is 
evidence showing that PTEN modulates hyperglycemia 
and insulin resistance [54]. In addition, PTEN deletion 
in pancreatic α-cells protects against HFD-induced insu-
lin resistance [55]. PTEN, through its lipid phosphatase 
activity, catalyzes the conversion of PIP3 (Akt substrate) 
to PIP2 by dephosphorylating the 3-position of the ino-
sitol ring of PIP3, attenuating Akt/eNOS/NO signaling 
[56].
PTEN expression changes under different conditions. 
PTEN mRNA decreases in the adipose tissue after expo-
sure to cold, but increases with obesity [57]. The pre-
sent study shows that HFD-fed C57Bl/6J mice exhibit 
increased vascular expression and activity of this phos-
phatase. Of importance, TNF-α receptor deletion pre-
vented HFD-induced increased PTEN expression and 
activity. Experimental evidence indicates that NF-kappaB 
signaling pathway is the link between TNF-α and PTEN 
in leukemic [22], glioma [58] and intestinal cells [59]. 
Mechanisms linking TNF-α receptor and PTEN activa-
tion/expression were not investigated, which represents a 
limitation of our study.
One of the mechanisms that regulate PTEN activ-
ity is reversible oxidation of the cysteine residue at the 
phosphatase active site [60]. Accordingly, treatment of 
macrophages with lipopolysaccharide stimulates ROS 
production and increases the fraction of oxidized PTEN 
from 5 to 16  % [61], showing a crosstalk between ROS 
production by the immune system and PTEN regulation.
In hepatocytes TNF-α increases PTEN expression, 
which is blunted by PTEN siRNA knockdown and VO-
OHpic treatment [62]. These results suggest an impor-
tant crosstalk between inflammatory mediators and 
PTEN activity and are in line with the idea that PTEN is 
involved in apoptosis and inflammatory processes [18]. 
Our findings indicate that TNF-α is a positive modula-
tor of PTEN activity. Since PTEN inhibition restores vas-
cular insulin sensitivity, decreased by TNF-α and HFD, 
PTEN may be considered a major contributor to TNF-α-
induced insulin resistance.
The mechanisms whereby PTEN changes vascu-
lar function are poorly understood. Our data indicate 
that TNF-α via increased PTEN expression and activity 
compromises NO bioavailability. Accordingly, mesen-
teric arteries incubated with TNF-α present reduced 
sensitivity to insulin effects as well as reduced Akt/eNOS 
signaling and NO levels. PTEN inhibition improved insu-
lin-dependent vasodilation, and restored NO levels, as 
indicated by the effects of L-NAME on insulin-induced 
vascular relaxation. In addition, TNF-α is the major reg-
ulator of PTEN activity in the vasculature of HFD-fed 
mice, decreasing Akt/eNOS/NO signaling. Our findings 
corroborate a previous report showing decreased NO 
release by human aortic endothelial cells overexpressing 
PTEN [63]. On the other hand, NO by inducing S-nitros-
ylation and ubiquitination, modulates both PTEN protein 
degradation and enzymatic activity in neurons, repre-
senting a regulatory mechanism of the Akt/NOS signal-
ing pathway on PTEN [64].
Conclusions
Taken together, our study suggests that in obesity, TNF-α 
induces vascular insulin resistance by increasing PTEN 
activity that negatively modulates Akt/eNOS/NO sign-
aling and insulin vasodilation. Since vascular insulin 
resistance represents a primary defect in vascular dys-
function, TNF-α and PTEN are potential therapeutic tar-
gets for obesity-associated cardiovascular and metabolic 
dysfunction.
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